10.15.19
Pharm-Olam, a global midsized contract research organization (CRO), has named Robert Davie, Ph.D., as its new chief executive officer. Pharm-Olam provides full-service clinical development solutions for oncology-hematology, infectious disease, vaccines, and rare diseases.
Davie succeeds David Grange who has served as Pharm-Olam’s chief executive since April 2017. Grange will remain a director and vice chairman of the company’s board and will continue to support the organization and its work in U.S. government-funded research, which is an expanding area of Pharm-Olam’s business.
“Rob Davie is a respected leader who has worked within the CRO industry for over 25 years. We look forward to his leadership and knowledge supporting the continued growth of Pharm-Olam,” said Zev Munk, founder and chairman of the board, Pharm-Olam. “We also extend our sincere thanks to David Grange for his leadership over the past two-and-a-half years, having transformed Pharm-Olam’s therapeutic focus while achieving record sales for 2018.”
Davie previously held critical roles within Covance, most recently as vice president and general manager of global clinical development.
Davie succeeds David Grange who has served as Pharm-Olam’s chief executive since April 2017. Grange will remain a director and vice chairman of the company’s board and will continue to support the organization and its work in U.S. government-funded research, which is an expanding area of Pharm-Olam’s business.
“Rob Davie is a respected leader who has worked within the CRO industry for over 25 years. We look forward to his leadership and knowledge supporting the continued growth of Pharm-Olam,” said Zev Munk, founder and chairman of the board, Pharm-Olam. “We also extend our sincere thanks to David Grange for his leadership over the past two-and-a-half years, having transformed Pharm-Olam’s therapeutic focus while achieving record sales for 2018.”
Davie previously held critical roles within Covance, most recently as vice president and general manager of global clinical development.